Clinical

Clinical  ·  Weekly Digest 19 April to 25 April 2025
Enhertu plus Pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive metastatic Breast cancer

Weekly Digest – April 2025 Weekly Digest – April 2025 21 Apr 2025: Enhertu plus Pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive metastatic Breast cancer The […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest 19 April to 25 April 2025
Gilead Sciences reports positive data From Phase 3 ASCENT-04/KEYNOTE-D19 study

Weekly Digest – April 2025 Weekly Digest – April 2025 21 Apr 2025: Gilead Sciences reports positive data From Phase 3 ASCENT-04/KEYNOTE-D19 study The Phase 3 ASCENT-04 trial showed that Trodelvy combined with Keytruda significantly improved progression-free survival compared to […]

by Sandhya Ramalingam

Continue Reading